Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketamine + xylazine is a widely used **injectable veterinary anesthetic combination** that pairs the dissociative anesthetic ketamine with the alpha-2 adrenergic agonist sedative xylazine to produce balanced anesthesia, analgesia, and muscle relaxation, particularly in small laboratory animals and other veterinary species.[1][2][3][6][9] Ketamine acts primarily as a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist to induce dissociative anesthesia and potent analgesia with relative preservation of respiratory drive, while also interacting with opioid, serotonin, GABA, sigma, and dopamine receptors.[2][6] Xylazine is an α2-adrenergic receptor agonist that provides sedation, analgesia, amnesia, and muscle relaxation and serves as an adjunct to ketamine to counteract ketamine-induced muscle hypertonicity, improve immobilization, and reduce the dose of ketamine required.[1][2][6][9] The combination is recommended for short-term, well-balanced anesthesia in many animal protocols, but can cause bradycardia, hypotension, respiratory depression, and hypothermia, and xylazine’s effects can be reversed with α2-adrenergic antagonists such as atipamezole or yohimbine.[1][6][9] It is not approved for human medical use as a fixed combination, and its use is largely restricted to veterinary anesthesia and research animal procedures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine + xylazine.